Perigon Wealth Management LLC Increases Holdings in Becton, Dickinson and Company (NYSE:BDX)

Posted by on Mar 18th, 2023

Perigon Wealth Management LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 18.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,738 shares of the medical instruments supplier’s stock after purchasing an additional 422 shares during the quarter. Perigon Wealth Management LLC’s holdings in Becton, Dickinson and were worth $610,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. Western Pacific Wealth Management LP bought a new stake in Becton, Dickinson and during the third quarter valued at $30,000. Chilton Capital Management LLC bought a new stake in Becton, Dickinson and during the second quarter valued at $39,000. SJS Investment Consulting Inc. bought a new stake in Becton, Dickinson and during the third quarter valued at $36,000. New Millennium Group LLC bought a new stake in Becton, Dickinson and during the second quarter valued at $44,000. Finally, Coston McIsaac & Partners bought a new stake in Becton, Dickinson and during the second quarter valued at $44,000. 87.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and

In related news, EVP Richard Byrd sold 1,421 shares of the business’s stock in a transaction dated Friday, February 3rd. The stock was sold at an average price of $248.60, for a total transaction of $353,260.60. Following the transaction, the executive vice president now owns 4,119 shares in the company, valued at approximately $1,023,983.40. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.31% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. Bank of America raised Becton, Dickinson and from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $250.00 to $290.00 in a research note on Tuesday, January 3rd. Citigroup raised Becton, Dickinson and from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $221.00 to $250.00 in a research note on Monday, December 12th. Piper Sandler lifted their price target on Becton, Dickinson and from $245.00 to $260.00 and gave the stock a “neutral” rating in a research note on Thursday, February 2nd. The Goldman Sachs Group dropped their price target on Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating for the company in a research note on Wednesday, November 23rd. Finally, StockNews.com began coverage on Becton, Dickinson and in a research note on Thursday. They set a “buy” rating for the company. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Becton, Dickinson and has an average rating of “Moderate Buy” and an average price target of $271.89.

Becton, Dickinson and Trading Down 1.0 %

NYSE BDX opened at $235.58 on Friday. Becton, Dickinson and Company has a 1-year low of $215.90 and a 1-year high of $277.29. The company has a current ratio of 1.07, a quick ratio of 0.60 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average of $244.55 and a 200-day moving average of $241.73. The firm has a market cap of $66.88 billion, a PE ratio of 44.45, a price-to-earnings-growth ratio of 2.46 and a beta of 0.53.

Becton, Dickinson and (NYSE:BDX – Get Rating) last released its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.30. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The company had revenue of $4.59 billion during the quarter, compared to analyst estimates of $4.59 billion. During the same quarter in the previous year, the company posted $3.64 EPS. Becton, Dickinson and’s revenue for the quarter was down 2.8% on a year-over-year basis. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.19 EPS for the current year.

Becton, Dickinson and Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 31st. Investors of record on Friday, March 10th will be issued a dividend of $0.91 per share. The ex-dividend date of this dividend is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a yield of 1.55%. Becton, Dickinson and’s dividend payout ratio is presently 68.68%.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.